Empowering Minds · Mental Health Europe

Are Psychedelics the New Frontier in Mental Health? | Episode 11

·37 min·3 clips

Joanna Moncrief reveals there's no evidence depression arises from a brain abnormality—it's a response to life circumstances.

This episode examines the potential role of psychedelics in mental health care, featuring Dr. Sarah Tai, a clinical psychology professor and psychedelics researcher, and Dr. Joanna Moncrieff, a critical psychiatry professor. The discussion is framed by Australia's 2023 decision to authorize psychiatrist-prescribed psychedelics for psychotherapy. Classical psychedelics are defined as substances like LSD, psilocybin, mescaline, and DMT, which create altered states of consciousness and heightened perception. Dr. Moncrieff identifies commercial interests, including pharmaceutical marketing of esketamine and tech industry investments in clinics, as key drivers of the current hype. She argues that depression is not caused by a proven brain abnormality but is a response to adverse social and personal circumstances. Dr. Tai suggests psychedelics might help by reducing brain activity linked to emotional control strategies, potentially allowing people to process difficult emotions differently. Both guests emphasize that psychedelics are not a universal cure and must be paired with psychotherapy. A significant ethical concern is the lack of long-term safety data for repeated psychedelic use, with ketamine's trajectory cited as a cautionary example. Dr. Tai highlights the challenge of obtaining truly informed consent for an experience patients cannot fully anticipate beforehand. The rollout in Australia is noted as being limited to specific conditions like MDMA for trauma and psilocybin for depression. Dr. Tai expresses concern that a medically-focused model may overlook the trans-diagnostic applications of psychedelics and create accessibility issues due to high therapy costs. Current research is criticized for primarily involving white, middle-class populations, neglecting cultural, religious, and minority group perspectives. The episode calls for specific clinical guidelines and specialized therapist training to ensure culturally sensitive and safe practices. Dr. Moncrieff advocates for a shift in mental health research away from a disease-focused medical model toward social science methodologies that examine community support and life circumstances. The tone is exploratory and cautionary, balancing academic expertise with critical analysis of commercial and medical systems. Listeners interested in the nuanced ethics, commercial pressures, and cultural considerations of psychedelic therapy will find this episode valuable. Those seeking a straightforward endorsement of psychedelics as a revolutionary treatment may find the skeptical and socially-focused perspective less appealing.

As heard by us

A careful look at psychedelic treatment that keeps its promise, limits, and risks in view.

Empowering Minds treats psychedelics and mental health with restraint, asking whether they are a genuine frontier or just being cast as one. It keeps the Australian medicine regulator's July 1, 2023 decision in view, while staying grounded in what the evidence can support for…

Read the full review in PlayNext →

Why you'd press play

If you want a grounded take on psychedelic therapy, start here.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from Empowering Minds